Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates

被引:24
作者
Kaempffe, Anna [1 ,2 ]
Dickgiesser, Stephan [2 ]
Rasche, Nicolas [2 ]
Paoletti, Andrea [3 ]
Bertotti, Elisa [3 ]
De Salve, Ilse [3 ]
Sirtori, Federico Riccardi [3 ]
Kellner, Roland [2 ]
Konning, Doreen [2 ]
Hecht, Stefan [2 ]
Anderl, Jan [2 ]
Kolmar, Harald [1 ]
Schroeter, Christian [2 ]
机构
[1] Tech Univ Darmstadt, Inst Organ Chem & Biochem, Alarich Weiss Str 4, D-64287 Darmstadt, Germany
[2] Antibody Drug Conjugates & Targeted NBE Therapeut, Frankfurter Str 250, D-64293 Darmstadt, Germany
[3] RBM SpA, Merck KGaA, NBE DMPK Discovery & Preclin Bioanalyt, Via Ribes 1, I-10010 Colleretto Giacosa, TO, Italy
关键词
Antibody Drug Conjugate(s) (ADC); Pharmacokinetics; Clearance; Conjugation; Stability; EFFICIENT PREPARATION; MOUSE MODELS; FCRN; ADC; IMPACT; LINKER; IDENTIFICATION; OPTIMIZATION; MECHANISM; IMPROVES;
D O I
10.1016/j.xphs.2021.08.002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Appropriate selection of conjugation sites and conjugation technologies is now widely accepted as crucial for the success of antibody-drug conjugates (ADCs). Herein, we present ADCs conjugated by different conjugation methods to different conjugation positions being systematically characterized by multiple in vitro assays as well as in vivo pharmacokinetic (PK) analyses in transgenic Tg276 mice. Conjugation to cysteines, genetically introduced at positions N325, L328, S239, D265, and S442, was compared to enzymatic conjugation via microbial transglutaminase (mTG) either to C-terminal light (LC) or heavy chain (HC) recognition motifs or to endogenous position Q295 of a native antibody. All conjugations yielded homogeneous DAR 2 ADCs with similar hydrophobicity, thermal stability, human neonatal Fc receptor (huFcRn) binding, and serum stability properties, but with pronounced differences in their PK profiles. mTG-conjugated ADC variants conjugated either to Q295 or to LC recognition motifs showed superior PK behavior. Within the panel of engineered cysteine variants L328 showed a similar PK profile compared to previously described S239 but superior PK compared to S442, D265, and N325. While all positions were first tested with trastuzumab, L328 and mTG LC were further evaluated with additional antibody scaffolds derived from clinically evaluated monoclonal antibodies (mAb). Based on PK analyses, this study confirms the newly described position L328 as favorable site for cysteine conjugation, comparable to the well-established engineered cysteine position S239, and emphasizes the favorable position Q295 of native antibodies and the tagged LC antibody variant for enzymatic conjugations via mTG. In addition, hemizygous Tg276 mice are evaluated as an adequate model for ADC pharmacokinetics, facilitating the selection of suitable ADC candidates early in the drug discovery process. (c) 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:3776 / 3785
页数:10
相关论文
共 67 条
[1]   Contribution of linker stability to the activities of anticancer immunoconjugates [J].
Alley, Stephen C. ;
Benjamin, Dennis R. ;
Jeffrey, Scott C. ;
Okeley, Nicole M. ;
Meyer, Damon L. ;
Sanderson, Russell J. ;
Senter, Peter D. .
BIOCONJUGATE CHEMISTRY, 2008, 19 (03) :759-765
[2]  
Anderl J, 2017, Patent, Patent No. 2017149077
[3]   Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies [J].
Avery, Lindsay B. ;
Wang, Mengmeng ;
Kavosi, Mania S. ;
Joyce, Alison ;
Kurz, Jeffrey C. ;
Fan, Yao-Yun ;
Dowty, Martin E. ;
Zhang, Minlei ;
Zhang, Yiqun ;
Cheng, Aili ;
Hua, Fei ;
Jones, Hannah M. ;
Neubert, Hendrik ;
Polzer, Robert J. ;
O'Hara, Denise M. .
MABS, 2016, 8 (06) :1064-1078
[4]   Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation [J].
Bai, Chen ;
Reid, Emily E. ;
Wilhelm, Alan ;
Shizuka, Manami ;
Maloney, Erin K. ;
Laleau, Rassol ;
Harvey, Lauren ;
Archer, Katie E. ;
Vitharana, Dilrukshi ;
Adams, Sharlene ;
Kovtun, Yelena ;
Miller, Michael L. ;
Chari, Ravi ;
Keating, Thomas A. ;
Yoder, Nicholas C. .
BIOCONJUGATE CHEMISTRY, 2020, 31 (01) :93-103
[5]   Investigation into Temperature-Induced Aggregation of an Antibody Drug Conjugate [J].
Beckley, Nia S. ;
Lazzareschi, Kathlyn P. ;
Chih, Hung-Wei ;
Sharma, Vikas K. ;
Flores, Heather L. .
BIOCONJUGATE CHEMISTRY, 2013, 24 (10) :1674-1683
[6]   Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer [J].
Bruno, R ;
Washington, CB ;
Lu, JF ;
Lieberman, G ;
Banken, L ;
Klein, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (04) :361-369
[7]  
Chartash EK, 2013, Patent, Patent No. 8557239
[8]   Identification and Localization of Unpaired Cysteine Residues in Monoclonal Antibodies by Fluorescence Labeling and Mass Spectrometry [J].
Chumsae, Chris ;
Gaza-Bulseco, Georgeen ;
Liu, Hongcheng .
ANALYTICAL CHEMISTRY, 2009, 81 (15) :6449-6457
[9]   Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides [J].
Datta-Mannan, Amita .
DRUG METABOLISM AND DISPOSITION, 2019, 47 (10) :1100-1110
[10]   Site-Specific Conjugation of Native Antibodies Using Engineered Microbial Transglutaminases [J].
Dickgiesser, Stephan ;
Rieker, Marcel ;
Mueller-Pompalla, Dirk ;
Schroeter, Christian ;
Tonillo, Jason ;
Warszawski, Shira ;
Raab-Westphal, Sabine ;
Kuehn, Stefanie ;
Knehans, Tim ;
Koenning, Doreen ;
Dotterweich, Julia ;
Betz, Ulrich A. K. ;
Anderl, Jan ;
Hecht, Stefan ;
Rasche, Nicolas .
BIOCONJUGATE CHEMISTRY, 2020, 31 (04) :1070-1076